Ursodiol Prescriptions Following Bariatric Surgery: National Prescribing Trends and Outcomes

Obes Surg. 2023 Aug;33(8):2361-2367. doi: 10.1007/s11695-023-06710-3. Epub 2023 Jul 1.

Abstract

Background: Rapid weight loss after bariatric surgery is a risk factor for gallstone development. Numerous studies have shown that ursodiol after surgery decreases rates of gallstone formation and cholecystitis. Real-world prescribing practices are unknown. This study aimed to examine prescription patterns for ursodiol and reassess its impact on gallstone disease using a large administrative database.

Methods: The Mariner database (PearlDiver, Inc.) was queried using Current Procedural Terminology codes for Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) between 2011 and 2020. Only patients with International Classification of Disease codes for obesity were included. Patients with pre-operative gallstone disease were excluded. The primary outcome was gallstone disease within 1 year, which was compared between patients who did and did not receive an ursodiol prescription. Prescription patterns were also analyzed.

Results: Three hundred sixty-five thousand five hundred patients fulfilled inclusion criteria. Twenty-eight thousand seventy-five (7.7%) patients were prescribed ursodiol. There was a statistically significant difference in development of gallstones (p < 0.001), development of cholecystitis (p = .049), and undergoing cholecystectomy (p < 0.001). There was a statistically significant decrease in the adjusted odds ratio (aOR) for the development of gallstones (aOR 0.81, 95% CI: 0.74, 0.89), development of cholecystitis (aOR 0.59, 95% CI: 0.36, 0.91), and undergoing cholecystectomy (aOR 0.75, 95% CI: 0.69, 0.81).

Conclusion: Ursodiol significantly decreases the odds of development of gallstones, cholecystitis, or cholecystectomy within 1 year following bariatric surgery. These trends hold true when analyzing RYGB and SG separately. Despite the benefit of ursodiol, only 10% of patients received an ursodiol prescription postoperatively in 2020.

Keywords: Actigall; Bariatric surgery; Cholecystectomy; Cholecystitis; Cholelithiasis; Ursodiol.

MeSH terms

  • Bariatric Surgery* / adverse effects
  • Cholecystitis* / complications
  • Cholecystitis* / surgery
  • Gallstones* / etiology
  • Gallstones* / surgery
  • Gastrectomy / adverse effects
  • Gastric Bypass* / adverse effects
  • Humans
  • Obesity, Morbid* / surgery
  • Postoperative Complications / etiology
  • Retrospective Studies
  • Ursodeoxycholic Acid

Substances

  • Ursodeoxycholic Acid